Infrequent occurrence of high-risk human papillomavirus and of p53 mutation in minimal deviation adenocarcinoma of the cervix

International Journal of Gynecological Pathology

Volumn 18, Issue 3, 1999, Pages 215-219

  Toki, Toshihiko ^a   Zhai, Ya Li ^a   Park, Jong Sup ^b   Fujii, Shingo ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b The Catholic University of Korea   (South Korea)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Human papillomavirus; Minimal deviation adenocarcinoma; p53; Uterine cervix

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER RISK; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 0033054328     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199907000-00005     Document Type: Article

References (41)

1. Gissman L, Schneider A. Human papillomavirus DNA in preneoplastic and neoplastic genital lesions. In: Peto R, zur Hausen H, eds. Viral etiology of cervical cancer. New York, NY: Cold Spring Harbor Laboratory, 1986:217-24.
2. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-63.
3. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.
4. Tase T, Okagaki T, Clark BA, Manias DA, Ostrow RS, Twiggs LB, Paras AJ. Human papillomavirus types and localization in adenocarcinoma and adenosquamous carcinoma of the uterine cervix: a study by in situ DNA hybridization. Cancer Res 1988;48:993-8.
5. Leminen A, Paavonen J, Vesterinen E, Wahlstrom T, Rantala I, Lehtinen M. Human papillomavirus types 16 and 18 in adenocarcinoma of the uterine cervix. Am J Clin Pathol 1991;95:647-52.
6. Hording U, Teglbjaerg CS, Visfeldt J, Bock JE. Human papillomavirus types 16 and 18 in adenocarcinoma of the uterine cervix. Gynecol Oncol 1992;46:313-6.
7. Yamakawa Y, Forslund O, Teshima H, Hasumi K, Kitagawa T, Hansson BG. Human papillomavirus DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix detected by polymerase chain reaction (PCR). Gynecol Oncol 1994;53:190-5.
8. Duggan MA, McGregor SE, Benoit JL, Inoue M, Nation JG, Stuart GC. The human papillomavirus status of invasive cervical adenocarcinoma: a clinicopathological and outcome analysis. Hum Pathol 1995;26:319-25.
9. Jiko K, Tsuda H, Sato S, Hirohashi S. Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus. Int J Cancer 1994;59:601-6.
10. Tenti P, Pavanello S, Padovan L, et al. Analysis of clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix. Am J Pathol 1998;152:1057-63.
11. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
12. Dyson N, Howley PM, Münger K, Harlow E. The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
13. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
14. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994 ;57:1-9.
15. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutations in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet 1992;339:1070-3.
16. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 1992;52:5323-8.
17. Paquette RL, Lee YY, Wilczynski SP, Karmakar A, Kizaki M, Miller CW, Koeffler HP. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 1993;72:1272-80.
18. Busby-Earle RM, Steel CM, Williams AR, Cohen B, Bird CC. p53 mutations in cervical carcinogenesis-low frequency and lack of correlation with human papillomavirus status. Er J Cancer 1994;69:732-7.
19. McKelvey JL, Goodlin RR. Adenoma malignum of the cervix. A cancer of deceptively innocent histologic pattern. Cancer 1963;16:549-57.
20. Silverberg SG, Hurt WG. Minimal deviation adenocarcinoma ("adenoma malignum") of the cervix: a reappraisal. Am J Obstet Gynecol 1975;121:971-5.
21. Gilks CB, Young RH, Aguirre P, DeLellis RA, Scully RE. Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases. Am J Surg Pathol 1989;13:717-29.
22. Wright TC, Ferenczy A, Kurman RJ. Carcinoma and other tumors of the cervix. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract, 4th ed. New York, NY: Springer-Verlag, 1994:279-326.
23. McGowan L, Young RH, Scully RE. Peutz-Jeghers syndrome with "adenoma malignum" of the cervix. A report of two cases. Gynecol Oncol 1980;10:125-33.
24. Young RH, Scully RE. Mucinous ovarian tumors associated with mucinous adenocarcinomas of the cervix. A clinicopathological analysis of 16 cases. Int J Gynecol Pathol 1988;7:99-111.
25. Agorastos T, Vakiani A, Papaloucas A. Minimal deviation adenocarcinoma of the cervix: a hypodiploid tumor? Int J Gynecol Pathol 1994;13:211-9.
26. Toki T, Shiozawa T, Hosaka N, Ishii K, Nikaido T, Fujii S. Minimal deviation adenocarcinoma of the uterine cervix has abnormal expression of sex steroid receptors. CA125, and gastric mucin. Int J Gynecol Pathol 1997;16:111-6.
27. Ishii K, Hosaka N, Toki T, Momose M, Hidaka E, Tsuchiya S, Katsuyama T. A new view of the so-called adenoma malignum of the uterine cervix. Virchows Arch 1998;432:315-22.
28. Lee JY, Dong SM, Kim HS, et al. A distinct region of chromosome 19p13.3 associated with the sporadic form of adenoma malignum of the uterine cervix. Cancer Res 1998;58:1140-3.
29. Fukushima M, Shimano S, Yamakawa Y, Hashimoto M, Yamaguchi T, Sawada Y, Fujinaga K. The detection of human papillomavirus (HPV) in a case of minimal deviation adenocarcinoma of the uterine cervix (adenoma malignum) using in situ hybridization. Jpn J Clin Oncol 1990;20:407-12.
30. Park JS, Jones RW, McLean MR, Currie JL, Woodruff JD, Shah KV, Kurman RJ. Possible etiologic heterogeneity of vulvar intraepithelial neoplasia. A correlation of pathologic characteristics with human papillomavirus detection by in situ hybridization and polymerase chain reaction. Cancer 1991;67:1599-607.
31. Banerjee SK, Makdisi WF, Weston AP, Mitchell SM, Campbell DR. Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. BioTechniques 1995;18:768-74.
32. Nuovo GJ. A starter's guide to in situ PCR: the start-up protocol. In: PCR in situ hybridization, 2nd ed. New York, NY: Raven Press, 1994:214-46.
33. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 1992;52:3674-8.
34. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
35. Holm R, Skomedal H, Helland A, Kristensen G, Borresen AL, Nesland JM. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 1993;169:21-6.
36. Tsuda H, Jiko K, Tsugane S, et al. Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Jpn J Cancer Res 1995;86:1049-53.
37. McCluggage G, McBride H, Maxwell P, Bharucha H. Immunohistochemical detection of p53 and bcl-2 proteins in neoplastic and non-neoplastic endocervical glandular lesions. Int J Gynecol Pathol 1997;16:22-7.
38. waf1/cip1 in adenocarcinoma Of the uterine cervix. A possible immunohistochemical marker of a favorable prognosis. Cancer 1998;82:2409-17.
39. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunohistochemical analysis of the human nuclear phosphoprotein p53. J Immunol Method 1992;151:237-44.
40. Schenkman NS, Sesterhenn IA, Washington L, et al. Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. J Urol 1995;154:617-21.
41. Zhai Y-L, Kobayashi Y, Mon A, Orii A, Nikaido T, Konishi I, Fujii S. Expression of steroid receptors, Ki-67 and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999;18:20-28.